The National Medical Products Administration approved the listing of Matuzumab Injection

Recently, the National Medical Products Administration approved the marketing of the Matuximab injection reported by Pfizer Inc., which is used for the routine prophylactic treatment of 12 years and older children and adult patients with a body weight 35 kg who have the following diseases to prevent bleeding or reduce the frequency of bleeding episodes: severe hemophilia A without inhibitors of coagulation factor VIII (congenital deficiency of coagulation factor VIII, FVIII).